Loading...
01/10 16:23
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals a mixed performance with a 4% revenue increase but a significant drop in EBIT and net profit, indicating financial struggles. The guidance remains flat, and management's vague responses in the Q&A add uncertainty. Competitive pressures, regulatory issues, and economic factors pose risks. Despite positive cash flow and R&D investments, the negative trends in manufacturing and software revenues, coupled with unclear future projections, suggest a negative sentiment. The lack of market cap data prevents a more precise prediction, but the overall sentiment leans negative.
Total Revenue €66.4 million, an increase of more than 4% year-over-year.
EBIT €0.6 million, down from €2.7 million year-over-year.
Net Result Loss of €0.5 million or €0.01 per share, compared to a profit of €3.6 million in Q1 2024.
Net Cash Position €67.7 million, an increase of almost €7 million compared to the beginning of the quarter.
Adjusted EBIT €0.6 million, down from €2.7 million year-over-year, representing an adjusted EBIT margin of 1%.
Adjusted EBITDA €6.1 million, down from €8.1 million year-over-year, representing an adjusted EBITDA margin of 9.3%.
Gross Profit Margin 55.3%, down from 56.5% in Q1 2024.
R&D Expenses Increased by €2.4 million or 6.9% year-over-year, with more than €11 million spent on R&D.
Cash Flow from Operating Activities Almost €10 million for the first quarter.
Free Cash Flow €8 million for the quarter.
Deferred Revenue Increased by €1.9 million, totaling almost €49 million.
Manufacturing Revenue Change Decreased by 5.5% year-over-year.
Medical Revenue Change Increased by almost 19% year-over-year.
Software Revenue Change Decreased by around 6% year-over-year.
Mimics Flow: Launched a cloud-based platform that enhances segmentation and planning for medical cases, utilizing AI algorithms for improved efficiency.
Mimics Enlight CMF: Shortlisted for TCT awards, this tool reduces planning time for orthognathic cases to under 25 minutes.
3D-printed tracheal splint: Announced a clinical trial for a bio-resolvable splint for infants with tracheobronchomalacia, aiming to open a new market.
Magics 2025: Introduced performance enhancements and simplified licensing for flagship software, improving processing times for complex geometries.
Next-gen build processors: Launched two new processors that increase printing speed by 30-40% and support mid-market 3D-printing growth.
Medical business growth: Revenue increased by almost 19% in the Medical segment, driven by personalized solutions.
Aerospace segment growth: Sales grew by 23% in the aerospace segment, renewing long-term contracts with key customers.
Defense sector involvement: Reassessing involvement in the defense sector to strengthen aerospace positioning and create new opportunities.
Sustainability efforts: Achieved a 32% reduction in emissions in 2024, on track to meet a 55% reduction target by 2029.
Operational efficiencies: Improved operational processes led to a reduction of almost 700 tons of CO2 in raw materials.
Market positioning: Anticipating stabilization in the second half of 2025, maintaining revenue guidance of €270 million to €285 million.
R&D investments: Continued investments in R&D, particularly in Medical segments, with over €11 million spent in Q1 2025.
Competitive Pressures: Management highlighted the impact of competitive dynamics and industry changes as risks that could affect the company's future results.
Regulatory Issues: The company mentioned the need to comply with regulatory standards, particularly in the medical sector, which could pose challenges.
Supply Chain Challenges: There are ongoing supply chain challenges that could impact the availability of materials and production efficiency.
Economic Factors: Macroeconomic uncertainty and geopolitical turbulence were noted as significant risks affecting investment climates and overall business performance.
Foreign Exchange Fluctuations: The company experienced significant unfavorable effects from exchange rate fluctuations, impacting financial results.
Market Conditions: The uncertain market conditions have led to revenue decreases in the Software and Manufacturing segments, indicating a challenging business environment.
Investment Climate: The investment climate in core markets remains difficult, affecting revenue generation and operational performance.
Sustainability Goals: Target to cut absolute emissions by 55% by 2029, with a 32% reduction achieved in 2024.
Additive Manufacturing Growth: Focus on scaling additive manufacturing to make it easier, faster, and more reliable.
Mimics Flow Launch: Cloud-based platform launched to enhance segmentation and planning in medical applications.
Clinical Trial for TBM: Launch of a clinical trial for a 3D-printed tracheal splint for infants.
New Software Products: Introduction of Magics 2025 and next-gen build processors to enhance additive manufacturing capabilities.
Aerospace Segment Growth: 23% sales growth in aerospace segment, with renewed long-term contracts.
Defense Sector Engagement: Reassessing involvement in the defense sector to create new opportunities.
2025 Revenue Guidance: Expected consolidated revenue for 2025 in the range of €270 million to €285 million.
Adjusted EBIT Guidance: Maintaining adjusted EBIT guidance of €6 million to €10 million for the fiscal year.
Net Cash Position: The net cash position at the end of Q1 was €67.7 million, an increase of almost €7 million compared to the beginning of the quarter.
Free Cash Flow: Generated a positive free cash flow of €8 million over the quarter.
The earnings call reveals several negative factors: reduced revenue guidance, geopolitical and macroeconomic challenges, unfavorable foreign exchange impacts, and declining revenues in key segments. Despite some positive elements, like growth in the Medical segment and cost control efforts, the overall sentiment is negative due to reduced guidance and ongoing uncertainties, particularly in manufacturing and defense. The Q&A session did not alleviate concerns, with management providing vague responses about future growth and profitability. The lack of clear guidance and the negative financial trends suggest a likely negative stock price reaction.
The earnings call presents a mixed picture: strong growth in the Medical segment and improved gross margins are positive, but significant declines in Software and Manufacturing revenues, coupled with a net financial loss, are concerning. The Q&A reveals cautious optimism about future growth, but also highlights uncertainties, especially in the Manufacturing segment. The slight downward revision in guidance and management's vague responses further temper positive sentiment, resulting in a neutral outlook for the stock price.
The earnings call reveals a mixed performance with a 4% revenue increase but a significant drop in EBIT and net profit, indicating financial struggles. The guidance remains flat, and management's vague responses in the Q&A add uncertainty. Competitive pressures, regulatory issues, and economic factors pose risks. Despite positive cash flow and R&D investments, the negative trends in manufacturing and software revenues, coupled with unclear future projections, suggest a negative sentiment. The lack of market cap data prevents a more precise prediction, but the overall sentiment leans negative.
The earnings call highlights strong financial performance with a 14% revenue increase, improved margins, and successful acquisitions. Despite some management ambiguity during the Q&A, the optimistic guidance, new partnerships, and ongoing investments suggest positive market sentiment. The medical segment's growth and strategic partnerships are key catalysts for a potential stock price increase, likely in the 2% to 8% range.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
